BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 24913012)

  • 1. Addressing phenoconversion: the Achilles' heel of personalized medicine.
    Shah RR; Smith RL
    Br J Clin Pharmacol; 2015 Feb; 79(2):222-40. PubMed ID: 24913012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.
    Nahid NA; Johnson JA
    Expert Opin Drug Metab Toxicol; 2022 Nov; 18(11):769-785. PubMed ID: 36597259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine.
    Shah RR; Smith RL
    Drug Metab Dispos; 2015 Mar; 43(3):400-10. PubMed ID: 25519488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial.
    Cicali EJ; Elchynski AL; Cook KJ; Houder JT; Thomas CD; Smith DM; Elsey A; Johnson JA; Cavallari LH; Wiisanen K
    Clin Pharmacol Ther; 2021 Sep; 110(3):677-687. PubMed ID: 34231197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pitfalls and challenges associated with phenoconversion in forensic toxcicology.
    Drevin G; Picard N; Jousset N; Briet M; Abbara C
    Forensic Sci Int Genet; 2021 Mar; 51():102433. PubMed ID: 33278816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
    Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
    J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation between CYP2D6 Genotype, Phenotype and Therapeutic Drug Concentrations among Nortriptyline and Venlafaxine Users in Old Age Psychiatry.
    Berm E; Kok R; Hak E; Wilffert B
    Pharmacopsychiatry; 2016 Sep; 49(5):186-190. PubMed ID: 27101231
    [No Abstract]   [Full Text] [Related]  

  • 8. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
    Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
    J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenoconversion and therapeutic drug monitoring.
    de Leon J
    Br J Clin Pharmacol; 2015 Oct; 80(4):777-8. PubMed ID: 25881716
    [No Abstract]   [Full Text] [Related]  

  • 11. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
    de Leon J; Susce MT; Murray-Carmichael E
    Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of
    de Jong LM; Boussallami S; Sánchez-López E; Giera M; Tushuizen ME; Hoekstra M; Hawinkels LJAC; Rissmann R; Swen JJ; Manson ML
    Front Pharmacol; 2023; 14():1201906. PubMed ID: 37361233
    [No Abstract]   [Full Text] [Related]  

  • 14. CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders.
    Jallaq SA; Verba M; Strawn JR; Martin LJ; DelBello MP; Ramsey LB
    J Child Adolesc Psychopharmacol; 2021 Feb; 31(1):56-62. PubMed ID: 32845723
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study.
    Scherf-Clavel M; Frantz A; Eckert A; Weber H; Unterecker S; Deckert J; Reif A; Hahn M
    Int J Clin Pharm; 2023 Oct; 45(5):1107-1117. PubMed ID: 37166747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review.
    Klomp SD; Manson ML; Guchelaar HJ; Swen JJ
    J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32906709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct Effects of Inflammation on Cytochrome P450 Regulation and Drug Metabolism: Lessons from Experimental Models and a Potential Role for Pharmacogenetics.
    de Jong LM; Jiskoot W; Swen JJ; Manson ML
    Genes (Basel); 2020 Dec; 11(12):. PubMed ID: 33339226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics and therapeutic prospects in dementia.
    Cacabelos R
    Eur Arch Psychiatry Clin Neurosci; 2008 Mar; 258 Suppl 1():28-47. PubMed ID: 18344047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics and phenoconversion: the influence on side effects experienced by psychiatric patients.
    den Uil MG; Hut HW; Wagelaar KR; Abdullah-Koolmees H; Cahn W; Wilting I; Deneer VHM
    Front Genet; 2023; 14():1249164. PubMed ID: 37693320
    [No Abstract]   [Full Text] [Related]  

  • 20. The importance of phenoconversion when using the
    Cicali EJ; Wiisanen K
    Pharmacogenomics; 2022 Sep; 23(14):749-752. PubMed ID: 36102178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.